Logo image of IDYA

IDEAYA BIOSCIENCES INC (IDYA) Stock Fundamental Analysis

NASDAQ:IDYA - US45166A1025 - Common Stock

24.155 USD
-3 (-11.06%)
Last: 9/8/2025, 12:21:06 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IDYA. IDYA was compared to 541 industry peers in the Biotechnology industry. While IDYA has a great health rating, there are worries on its profitability. While showing a medium growth rate, IDYA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IDYA has reported negative net income.
IDYA had a negative operating cash flow in the past year.
IDYA had negative earnings in each of the past 5 years.
IDYA had negative operating cash flow in 4 of the past 5 years.
IDYA Yearly Net Income VS EBIT VS OCF VS FCFIDYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

IDYA has a better Return On Assets (-31.82%) than 65.43% of its industry peers.
The Return On Equity of IDYA (-34.52%) is better than 75.05% of its industry peers.
Industry RankSector Rank
ROA -31.82%
ROE -34.52%
ROIC N/A
ROA(3y)-18.98%
ROA(5y)-16.31%
ROE(3y)-20.3%
ROE(5y)-18.96%
ROIC(3y)N/A
ROIC(5y)N/A
IDYA Yearly ROA, ROE, ROICIDYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

IDYA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IDYA Yearly Profit, Operating, Gross MarginsIDYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

IDYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IDYA has been increased compared to 1 year ago.
IDYA has more shares outstanding than it did 5 years ago.
IDYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IDYA Yearly Shares OutstandingIDYA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IDYA Yearly Total Debt VS Total AssetsIDYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

IDYA has an Altman-Z score of 15.97. This indicates that IDYA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of IDYA (15.97) is better than 90.02% of its industry peers.
There is no outstanding debt for IDYA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.97
ROIC/WACCN/A
WACC9.65%
IDYA Yearly LT Debt VS Equity VS FCFIDYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M 1B

2.3 Liquidity

IDYA has a Current Ratio of 12.39. This indicates that IDYA is financially healthy and has no problem in meeting its short term obligations.
IDYA has a Current ratio of 12.39. This is amongst the best in the industry. IDYA outperforms 85.58% of its industry peers.
A Quick Ratio of 12.39 indicates that IDYA has no problem at all paying its short term obligations.
IDYA has a better Quick ratio (12.39) than 85.58% of its industry peers.
Industry RankSector Rank
Current Ratio 12.39
Quick Ratio 12.39
IDYA Yearly Current Assets VS Current LiabilitesIDYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

IDYA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -73.06%.
The Revenue for IDYA has decreased by -41.48% in the past year. This is quite bad
IDYA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -36.96% yearly.
EPS 1Y (TTM)-73.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.41%
Revenue 1Y (TTM)-41.48%
Revenue growth 3Y-36.96%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.92% on average over the next years. This is quite good.
Based on estimates for the next years, IDYA will show a very strong growth in Revenue. The Revenue will grow by 158.59% on average per year.
EPS Next Y-4.67%
EPS Next 2Y-0.85%
EPS Next 3Y2.52%
EPS Next 5Y12.92%
Revenue Next Year150.02%
Revenue Next 2Y210.49%
Revenue Next 3Y189.25%
Revenue Next 5Y158.59%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IDYA Yearly Revenue VS EstimatesIDYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
IDYA Yearly EPS VS EstimatesIDYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IDYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IDYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IDYA Price Earnings VS Forward Price EarningsIDYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDYA Per share dataIDYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.85%
EPS Next 3Y2.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IDYA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IDEAYA BIOSCIENCES INC

NASDAQ:IDYA (9/8/2025, 12:21:06 PM)

24.155

-3 (-11.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-03 2025-11-03
Inst Owners115.31%
Inst Owner Change1.71%
Ins Owners0.91%
Ins Owner Change0%
Market Cap2.12B
Analysts84.55
Price Target45.35 (87.75%)
Short Float %11.13%
Short Ratio9.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.42%
Min EPS beat(2)-21.53%
Max EPS beat(2)-9.31%
EPS beat(4)1
Avg EPS beat(4)-37.98%
Min EPS beat(4)-128.31%
Max EPS beat(4)7.25%
EPS beat(8)2
Avg EPS beat(8)-22.2%
EPS beat(12)6
Avg EPS beat(12)-2.84%
EPS beat(16)7
Avg EPS beat(16)-4.87%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-63.24%
Min Revenue beat(4)-100%
Max Revenue beat(4)47.06%
Revenue beat(8)2
Avg Revenue beat(8)-62.73%
Revenue beat(12)4
Avg Revenue beat(12)-11.88%
Revenue beat(16)6
Avg Revenue beat(16)-8.17%
PT rev (1m)2.1%
PT rev (3m)-11.72%
EPS NQ rev (1m)-5.68%
EPS NQ rev (3m)-20.19%
EPS NY rev (1m)-5.41%
EPS NY rev (3m)-9.4%
Revenue NQ rev (1m)7.64%
Revenue NQ rev (3m)57.1%
Revenue NY rev (1m)-19.43%
Revenue NY rev (3m)-14.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 302.42
P/FCF N/A
P/OCF N/A
P/B 2.21
P/tB 2.21
EV/EBITDA N/A
EPS(TTM)-3.79
EYN/A
EPS(NY)-3.36
Fwd EYN/A
FCF(TTM)-3.39
FCFYN/A
OCF(TTM)-3.35
OCFYN/A
SpS0.08
BVpS10.95
TBVpS10.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.82%
ROE -34.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.98%
ROA(5y)-16.31%
ROE(3y)-20.3%
ROE(5y)-18.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 144.02%
Cap/Sales 50.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.39
Quick Ratio 12.39
Altman-Z 15.97
F-Score2
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)140.34%
Cap/Depr(5y)121.83%
Cap/Sales(3y)23.99%
Cap/Sales(5y)16.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-73.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.41%
EPS Next Y-4.67%
EPS Next 2Y-0.85%
EPS Next 3Y2.52%
EPS Next 5Y12.92%
Revenue 1Y (TTM)-41.48%
Revenue growth 3Y-36.96%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year150.02%
Revenue Next 2Y210.49%
Revenue Next 3Y189.25%
Revenue Next 5Y158.59%
EBIT growth 1Y-100.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.42%
EBIT Next 3Y0.1%
EBIT Next 5YN/A
FCF growth 1Y-167.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-169.57%
OCF growth 3YN/A
OCF growth 5YN/A